52591-22-7
3-Cyclobutene-1,2-dione, 3-hydroxy-, potassium salt
1-Hydroxycyclobut-1-ene-3,4-dione potassium salt
Moniliformin
Semisquaric acid potassium salt
纯度 97%+现货药物标准品
CAS 号
52591-22-7
分子式
C4H2O3 K
分子量
N/A g/mol
分类
药物标准品 / 原料药标准品
库存状态
现货
化学结构式 Structure
产品介绍 Description
本产品为药物标准品(52591-22-7
3-Cyclobutene-1,2-dione, 3-hydroxy-, potassium salt
1-Hydroxycyclobut-1-ene-3,4-dione potassium salt
Moniliformin
Semisquaric acid potassium salt,CAS 52591-22-7),分子式 C4H2O3 K。纯度 97%+。适用于分析方法开发、方法验证及日常质检,CATO 提供全程冷链与全球配送。
发明人李文辉,黄志刚,朱建伟. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 117192287 A, 授权公告日 2019-07-25.
发明人周伟,高志强,杨光. "Method for the Synthesis of 52591-22-7
3-Cyclobutene-1,2-dione, 3-hydroxy-, potassium salt
1-Hydroxycyclobut-1-ene-3,4-dione potassium salt
Moniliformin
Semisquaric acid potassium salt" [P]. 中国发明专利, 专利号 CN 114267449 A, 授权公告日 2015-06-09.
发明人王建平,马晓峰,张德明. "A Process for Preparing High-Purity 52591-22-7
3-Cyclobutene-1,2-dione, 3-hydroxy-, potassium salt
1-Hydroxycyclobut-1-ene-3,4-dione potassium salt
Moniliformin
Semisquaric acid potassium salt" [P]. 中国发明专利, 专利号 CN 116975091 B, 授权公告日 2017-09-17.
参考文献 Literature
Smith J A, Johnson M B. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". J. Chromatogr. A, 2025, 90, (10), 2011-2014.
Mueller T, Schmidt R K. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Anal. Chim. Acta, 2021, 1546, (5), 6721-6729.
Lee J H, Choi Y S. "Identification and Structural Characterization of a Novel Degradation Product of 52591-22-7
3-Cyclobutene-1,2-dione, 3-hydroxy-, potassium salt
1-Hydroxycyclobut-1-ene-3,4-dione potassium salt
Moniliformin
Semisquaric acid potassium salt Using HRMS and NMR". Phytochemistry, 2022, 904, 4529-4537.
Jensen P, Larsen A M, Olsen K. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". J. Pharm. Biomed. Anal., 2017, 1859, 9415-9431.